(Q43657215)

English

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 November 2017

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study (English)

1 reference

Europe PubMed Central

25 November 2017

Igor N. Bondarenko

11

1 reference

Europe PubMed Central

25 November 2017

author name string

Tim Eisen

1

1 reference

Europe PubMed Central

25 November 2017

Yaroslav Shparyk

2

1 reference

Europe PubMed Central

25 November 2017

Nicholas Macleod

3

1 reference

Europe PubMed Central

25 November 2017

Robert Jones

4

1 reference

Europe PubMed Central

25 November 2017

Gudrun Wallenstein

5

1 reference

Europe PubMed Central

25 November 2017

Graham Temple

6

1 reference

Europe PubMed Central

25 November 2017

Yasser Khder

7

1 reference

Europe PubMed Central

25 November 2017

Claudia Dallinger

8

1 reference

Europe PubMed Central

25 November 2017

Matus Studeny

9

1 reference

Europe PubMed Central

25 November 2017

Arsene-Bienvenu Loembe

10

1 reference

Europe PubMed Central

25 November 2017

publication date

27 April 2013

1 reference

Europe PubMed Central

25 November 2017

Investigational New Drugs

1 reference

Europe PubMed Central

25 November 2017

31

1 reference

Europe PubMed Central

25 November 2017

5

1 reference

Europe PubMed Central

25 November 2017

1283-1293

1 reference

Europe PubMed Central

25 November 2017

https://scigraph.springernature.com/pub.10.1007/s10637-013-9962-7

0 references

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Timing of new black box warnings and withdrawals for prescription medications

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Cardiac toxicity: old and new issues in anti-cancer drugs.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Assessing proarrhythmic potential of drugs when optimal studies are infeasible.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23625328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New precompetitive paradigms: focus on cardiac safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/23625328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Baseline heart rate-corrected QT and eligibility for clinical trials in oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/23625328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23625328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-013-9962-7

1 reference

Europe PubMed Central

25 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43657215&oldid=2111277197"